Details

Autor(en) / Beteiligte

• Hamilton, SJ
• Chew, GT
• Davis, TME
• Stuckey, BGA
• Watts, GF

Titel

Hypertriglyceridaemia in statin-treated type 2 diabetic patients

Ist Teil von

• Practical diabetes international, 2011-07, Vol.28 (6), p.257-260

Ort / Verlag

Chichester, UK: John Wiley & Sons, Ltd

Erscheinungsjahr

2011

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• In this cross‐sectional study, we investigated the prevalence of hypertriglyceridaemia (hyperTG) in 182 statin‐treated type 2 diabetic (T2DM) patients. Predictors of hyperTG (≥2.3mmol/L) were investigated using logistic regression. The prevalence of hyperTG was 20.9%, with lower prevalence in patients with low‐density lipoprotein (LDL)‐cholesterol <2.5mmol/L (13.7%), and LDL‐cholesterol <2.0mmol/L (8.8%). The prevalence of hyperTG plus low high‐density lipoprotein (HDL)‐cholesterol (≤0.9mmol/L) was lower at 6.0%. The independent predictors of hyperTG were waist circumference (odds ratio [OR] 1.033 [95% confidence interval 1.004–1.063], p=0.027) and glucose (OR 1.30 [1.05–1.61], p=0.01), with glucose being the sole predictor in patients with LDL‐cholesterol <2.5mmol/L (OR 1.45 [1.11–1.89], p=0.01) and LDL‐cholesterol <2.0mmol/L (OR 1.59 [1.12–2.26], p=0.01). In this group of statin‐treated T2DM patients, the prevalence of hyperTG was relatively high, but lower in patients with lower LDL‐cholesterol levels. Residual hyperTG in statin‐treated patients could be addressed by therapeutic lifestyle interventions aimed at weight loss and improved glycaemic control and by further lowering of LDL‐cholesterol. Copyright © 2011 John Wiley & Sons.